

**Iowa Medicaid Pharmaceutical and Therapeutics (P & T) Committee Meeting
August 15, 2019****Location: Iowa State Capitol Room 116
1007 E. Grand Ave
Des Moines, IA 50319****Time: 9:30 a.m. – 4:30 p.m.****Tentative Agenda**

1. Welcome & Introductions
 - a) Committee Members and Staff
2. Committee Business
 - a) Approval of the minutes
 - b) Conflict of Interest Disclosure
 - c) Annual P&T Committee Chairperson and Vice Chairperson Elections
3. Update
 - a) Preferred Drug List (PDL)
 - b) Medicaid Drug Rebate Issues
 - c) Prior Authorization Criteria/Pro-DUR edits
 - d) Legislation
 - e) IME Updates
4. Public Comment **(See attachment 1 for Conflict of Interest Disclosure)**
5. Closed Executive Session
 - a) Approval of the minutes
 - b) Economic Review of the Iowa Medicaid Preferred Drug List, Newly Released Drugs, Newly Released Generic Drugs, New Dosage Forms, and Contracts
 - c) Review and discussion of the Confidential Public Comments
6. Recommended Drug List (PDL) discussion and deliberation
(See attachment 2 for order of discussion)
7. Final Recommendations by the P & T Committee on the Iowa Medicaid Recommended Drug List
8. Review of Newly Released Drugs
(See attachment 3 for order of discussion)
9. Final Recommendations by the P & T Committee on Newly Released Drugs (Open Session)
10. Review of Newly Released Generic Drugs, Dosage Forms or Strengths
(See attachment 4 for order of discussion)
11. Final Recommendations by the P & T Committee on Newly Released Generic Drugs, Dosage Forms or Strengths
12. Preview of next meeting

****Disclaimer: Executive Sessions may be necessary during the deliberation process****

www.IowaMedicaidPDL.com

Next scheduled meeting: November 21, 2019 9:30am - 4:30pm

For more information contact Erin Halverson at ehalver@dhs.state.ia.us or (515) 974-3126

Attachment 1

**Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee
Speaker Conflict of Interest Disclosure**

The Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee and persons speaking or presenting to the Iowa Medicaid P&T Committee are asked to disclose any financial or other affiliation with organizations that may have a direct or indirect interest in the business in front of the Committee. Those persons speaking or presenting at the P&T Committee meetings are asked to disclose potential conflicts on this form. P&T Committee members disclose potential conflicts each year on a separate form.

A financial interest may include, but is not limited to, being a shareholder in the organization, being on retainer with the organization, having research or honoraria paid by the organization, or receiving other forms of remuneration from an organization. An affiliation may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

The existence of such a financial relationships or affiliation does not necessarily constitute a conflict of interest and will not preclude an individual from participating or addressing the P&T Committee. This policy is intended to openly identify any potential conflicts so that the P&T Committee members and the public are able to form their own judgments.

Your responses below will be read out loud before your presentation to the P&T Committee.

Please check the box of the statement that best applies.

Statement of No Conflicts

I do not have a current or recent (within the last 12 months) financial arrangement or affiliation with any organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee.

Disclosures

I have a financial interest, affiliation or am employed by an organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee

I refuse to state my affiliations

Organization (List additional on the back of the form.)	Role/Relationship (List additional on the back of the form.)

(print name)

(signature)

(date)

Attachment 2

Iowa Medicaid Recommended Drug List

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P&T Committee Meeting when a competitor's product is on the agenda for discussion.

The changes below are recommended to maximize cost savings to the program unless otherwise noted:

1. Recommend to change Tarceva to Preferred with Conditions.

Attachment 3
Newly Released Drugs

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P & T Committee Meeting when a competitor's product is on the agenda for discussion.

1. Balversa- Recommend status on the RDL as Non-Recommended with Conditions
2. Firdapse- Recommend status on the PDL as Non-Preferred
3. Inbrija- Recommend status on the PDL as Preferred
4. Mavenclad- Recommended status on the PDL as Non-Preferred with DUR Referral
5. Mayzent- Recommend status on the PDL as Non-Preferred with DUR Referral
6. Motegrity- Recommend status on the PDL as Non-Preferred with Conditions
7. Osphe-na- Recommend status on the PDL as Non-Preferred with DUR Referral
8. Skyrizi- Recommend status on the PDL as Non-Preferred with Conditions
9. Valchlor- Recommend status on the PDL as Non-Preferred
10. Vitrakvi- Recommend status on the RDL as Non-Recommended with Conditions
11. Vyndaqel- Recommend status on the PDL as Non-Preferred

Attachment 4

Newly Released Generic Drugs, New Dosage Forms, New Drug Names, and New drug Strengths

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P&T Committee Meeting when a competitor's product is on the agenda for discussion.

NEWLY RELEASED GENERIC DRUGS/BIOSIMILARS		
Drug Name	Brand Name/Status on PDL/RDL	PDL/RDL Recommendation
Albuterol HFA	ProAir HFA / Preferred Ventolin HFA / Non-Preferred	Non-Preferred
Aliskiren	Tekturna / Non-Preferred	Non-Preferred
Ambrisentan	Letairis / Preferred with Conditions	Non-Preferred with Conditions
Bosentan	Tracleer / Preferred with Conditions	Non-Preferred with Conditions
Buprenorphine/ Naloxone SL Film	Suboxone / Non-Preferred with Conditions	Non-Preferred with Conditions
Deferasirox	Exjade / Preferred with Conditions	Non-Preferred with Conditions
Diclofenac Epolamine	Flector / Non-Preferred with Conditions	Non-Preferred with Conditions
Erlotinib	Tarceva / Preferred with Conditions	Non-Preferred with Conditions
Insulin Lispro Vial	Humalog / Preferred	Non-Preferred
Insulin Lispro Pen	Humalog KwikPen / Non-Preferred with Conditions	Non-Preferred with Conditions
Loteprednol	Lotemax / Non-Preferred	Non-Preferred
Mesalamine DR Cap	Delzicol / Preferred	Non-Preferred
Penicillamine	Cuprimine / Non-Preferred	Non-Preferred
Ranolazine	Ranexa / Non-Preferred	Non-Preferred
Solifenacin	Vesicare / Preferred	Non-Preferred
Treprostinil	Remodulin / Non-Preferred with Conditions	Non-Preferred with Conditions
Udenyca	Neulasta / Non-Preferred with Conditions	Non-Preferred with Conditions

NEW DRUG DOSAGE FORMS/STRENGTHS/COMBINATIONS

Adapalene Pads	Adapalene Gel / Preferred with Conditions	Non-Preferred with Conditions
Arikayce	Amikacin / Preferred	Non-Preferred
Cutaquig	Hizentra / Non-Preferred	Non-Preferred
Dovato	Lamivudine / Preferred Tivicay / Preferred	Non-Preferred
Duobrii	Halobetasol Propionate / Non-Preferred with conditions Tazorac / Preferred with Conditions	Non-Preferred with Conditions
Herceptin Hylecta	Herceptin / Medical Coverage	Non-Recommended with Conditions
Inveltys	Alrex / Preferred Lotemax / Non-Preferred	Non-Preferred
Qmiiz ODT	Meloxicam Tablets / Preferred	Non-Preferred with Conditions
Relexxii	Concerta / Preferred with Conditions	Non-Preferred with Conditions
Rocklatan	Latanoprost / Preferred Rhopressa / Preferred	Preferred
Sympazan	Clobazam Tablets & Oral Suspension / Preferred	Non-Preferred with Conditions
Tresiba Vial	Tresiba FlexTouch / Preferred	Preferred